Inclusion in ASX 200 another boost for Resolute

Published 05-SEP-2016 15:28 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

It has been a stellar 12 month period for Resolute Mining (ASX: RSG) and this is reflected in its share price which has increased from approximately 25 cents this time last year to hit a recent high of $2.10.

However, recent weakness in the gold price has seen it retrace approximately 15%, and Friday’s closing price of $1.87 implies a significant discount to most analyst’s price targets.

In reviewing the company’s fiscal 2016 performance last week, Trent Allen from Citi noted that fiscal 2016 wasn’t just a positive year for Resolute in terms of its operational performance, but it also was significant in terms of strengthening its balance sheet.

He noted that the stock is trading on a fiscal 2017 PE multiple of 5.3 (based on a share price of $1.77). Allen views this as relatively low given the company’s production growth through to fiscal 2020 at which point it is expected to be producing at a rate of 450,000 ounces per annum.

Allen said that he expects a further rerating through fiscal 2017 as development milestones are reached at Syama and Ravenswood. The following snapshot demonstrates the key strengths of the company’s operations.

Allen revised his earnings per share estimates for fiscal years 2017, 2018 and 2019 last week, upgrading his numbers by 22.4%, 18.7% and 40.2% respectively.

Another potential share price catalyst emerged on Friday with the announcement that Resolute would be included in the S&P/ASX 200 as at September 16, 2016.

This should increase the company’s institutional appeal, and this perhaps accounted for Friday’s circa 6% increase in share price which occurred under the third-highest volumes in the last 12 months.

Index bound institutions will need to wait for Resolute to be included in the ASX 200 on September 16 before buying into the stock which perhaps provides retail investors with an opportunity to move ahead of what could be a fairly intensive buying period.

However, it is worth noting that the rise and rise of Resolute over the last 12 months has resulted in significant institutional activity in the stock, indicating there is no guarantee that its inclusion will trigger a share price rerating.

This backdrop combined with the fact that Resolute’s key Syama gold mine is located in Mali, an area that carries sovereign risk suggests investors need to view the stock with a high degree of caution and bear in mind that any share price variations to date may not be replicated in the future. Furthermore, broker estimates should not be used as a basis for an investment decision.

While this represents a long list of caveats it could be argued that Allen’s observation regarding the company’s heavily discounted PE multiple accounts for some of the inherent risks.

He upgraded his 12 month price target from $1.80 to $2.04, implying upside of nearly 10% to Friday’s closing price. Duncan Hughes from Somers and Partners also upgraded his 12 month price target.

At a gold price of US$1300 per ounce his valuation and price target stands at $2.07, but increases to $2.40 at US$1400 per ounce, highlighting Resolute’s leverage to positive movements in the price of the precious metal.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free